(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 October 2009 (01.10.2009)

PCT

(10) International Publication Number
WO 2009/118142 A1

(51) International Patent Classification:
*A61K 39/395* (2006.01) *A61P 35/00* (2006.01)
*C07K 16/28* (2006.01)

(21) International Application Number:
PCT/EP2009/002111

(22) International Filing Date:
23 March 2009 (23.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08005554.4 25 March 2008 (25.03.2008) EP
08007172.3 11 April 2008 (11.04.2008) EP

(71) Applicants *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). **GLYCART BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 18, CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DUMONTET, Charles** [FR/FR]; 11 Chemin du Laquay, F-69200 Venissieux (FR). **FRIESS, Thomas** [DE/DE]; St. Martin Strasse 8a, 86911 Diessen-Dettenhofen (DE). **HERTING, Frank** [DE/DE]; An der Freiheit 29a, 82377 Penzberg (DE). **KLEIN, Christian** [DE/DE]; Moraenenweg 5, 82393 Iffeldorf (DE). **UMANA, Pablo** [CR/CH]; Freiestrasse 159, CH-8032 Zuerich (CH).

(74) Agent: **BURGER, Alexander**; Roche Diagnostics GMBH, Patent Department (TR-E), Postfach 11 52, 82372 Penzberg (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

*[Continued on next page]*

(54) **Title**: USE OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATING NON-HODGKIN' S LYMPHOMAS

**Fig. 4**




(57) **Abstract**: The present invention is directed to the use an type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with one ore more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.

WO 2009/118142 A1

— *of inventorship (Rule 4.17(iv))*

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*